首页> 外文期刊>Brain and cognition >Inhibition deficits are modulated by age and CGG repeat length in carriers of the FMR1 premutation allele who are mothers of children with fragile X syndrome
【24h】

Inhibition deficits are modulated by age and CGG repeat length in carriers of the FMR1 premutation allele who are mothers of children with fragile X syndrome

机译:抑制缺陷由FMR1的载体的载体中的年龄和CGG重复长度调节,患有脆弱的X综合征的儿童母亲

获取原文
获取原文并翻译 | 示例
       

摘要

Individuals who carry a premutation (PM) allele on the FMR1 gene may experience executive limitations associated with their genetic status, including inhibition deficits. However, poor understanding of individualized risk factors has limited clinical management of this group, particularly in mothers who carry the PM allele who have children with fragile X syndrome (FXS). The present study examined CGG repeat length and age as factors that may account for variable expressivity of inhibition deficits. Participants were 134 carriers of the PM allele who were mothers of children with FXS. Inhibition skills were measured using both self-report and direct behavioral assessments. Increased vulnerability for inhibition deficits was observed at mid-range CGG lengths of approximately 80-100 repeats, with some evidence of a second zone of vulnerability occurring at approximately 130-140 CGG repeats. Risk associated with the genotype also became more pronounced with older age. This study identifies personalized risk factors that may be used to tailor the clinical management of executive deficits in carriers of the PM allele. Inhibition deficits may contribute to poor outcomes in carriers of the PM allele and their families, particularly in midlife and early old age, and clinical monitoring may be warranted.
机译:在FMR1基因上进行优质(PM)等位基因的个人可能会遇到与其遗传地位相关的行政限制,包括抑制缺陷。然而,对个性化风险因素的理解不良,这一组的临床管理有限,特别是携带有脆弱X综合征(FXS)儿童的PM等位基因的母亲。本研究检测了CGG重复长度和年龄,作为可能算用于抑制缺陷的可变表现性的因素。参与者是PM等位基因的134个载体,他是有FXS的儿童母亲。使用自我报告和直接行为评估来测量抑制技能。在大约80-100重复的中档CGG长度下观察到抑制缺陷的脆弱性增加,其中一些脆弱性的一些证据发生在大约130-140 CGG重复。与基因型相关的风险也变得更加明显,年龄更加明显。本研究识别可用于量身定制PM等位基因载体中执行赤字的临床管理的个性化风险因素。抑制缺陷可能有助于PM等位基因及其家庭的载体中的差,特别是在中期和初龄年龄,并且可能需要临床监测。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号